153 related articles for article (PubMed ID: 26639227)
1. Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia.
Patel TS; Cottreau JM; Hirsch EB; Tam VH
Diagn Microbiol Infect Dis; 2016 Feb; 84(2):155-8. PubMed ID: 26639227
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia.
Su TY; Ye JJ; Hsu PC; Wu HF; Chia JH; Lee MH
J Microbiol Immunol Infect; 2015 Apr; 48(2):175-82. PubMed ID: 24064286
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
4. Tree-structured survival analysis of patients with Pseudomonas aeruginosa bacteremia: A multicenter observational cohort study.
Yoon YK; Kim HA; Ryu SY; Lee EJ; Lee MS; Kim J; Park SY; Yang KS; Kim SW;
Diagn Microbiol Infect Dis; 2017 Feb; 87(2):180-187. PubMed ID: 27863948
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome.
Jeong SJ; Yoon SS; Bae IK; Jeong SH; Kim JM; Lee K
Diagn Microbiol Infect Dis; 2014 Oct; 80(2):130-5. PubMed ID: 25112900
[TBL] [Abstract][Full Text] [Related]
6. A model to predict mortality following Pseudomonas aeruginosa bacteremia.
Hirsch EB; Cottreau JM; Chang KT; Caeiro JP; Johnson ML; Tam VH
Diagn Microbiol Infect Dis; 2012 Jan; 72(1):97-102. PubMed ID: 22056006
[TBL] [Abstract][Full Text] [Related]
7. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC
Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
[TBL] [Abstract][Full Text] [Related]
9. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.
Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A;
Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
[TBL] [Abstract][Full Text] [Related]
11. Systemic inflammatory response syndrome in nosocomial bloodstream infections with Pseudomonas aeruginosa and Enterococcus Species: comparison of elderly and nonelderly patients.
Marra AR; Bar K; Bearman GM; Wenzel RP; Edmond MB
J Am Geriatr Soc; 2006 May; 54(5):804-8. PubMed ID: 16696747
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
Kang CI; Kim SH; Kim HB; Park SW; Choe YJ; Oh MD; Kim EC; Choe KW
Clin Infect Dis; 2003 Sep; 37(6):745-51. PubMed ID: 12955633
[TBL] [Abstract][Full Text] [Related]
15. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa Bacteremia among Immunocompetent and Immunocompromised Patients: Relation to Initial Antibiotic Therapy and Survival.
Migiyama Y; Yanagihara K; Kaku N; Harada Y; Yamada K; Nagaoka K; Morinaga Y; Akamatsu N; Matsuda J; Izumikawa K; Kohrogi H; Kohno S
Jpn J Infect Dis; 2016; 69(2):91-6. PubMed ID: 26073727
[TBL] [Abstract][Full Text] [Related]
17. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.
Tam VH; Rogers CA; Chang KT; Weston JS; Caeiro JP; Garey KW
Antimicrob Agents Chemother; 2010 Sep; 54(9):3717-22. PubMed ID: 20585122
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.
Lee CC; Lee CH; Hong MY
Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263
[TBL] [Abstract][Full Text] [Related]
20. Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa.
Blot S; Vandewoude K; Hoste E; Colardyn F
J Hosp Infect; 2003 Jan; 53(1):18-24. PubMed ID: 12495681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
